Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 1/2007

01-01-2007 | Brief Report

Carnitine: a therapeutic option for childhood psoriatic onycho-pachydermo-periostitis (POPP)

Authors: Pieranna Fietta, Paolo Manganelli

Published in: Clinical Rheumatology | Issue 1/2007

Login to get access

Abstract

Psoriatic onycho-pachydermo-periostitis (POPP) is a rare subset of psoriatic arthritis, characterized by onychopathy, painful thickening of the periungual soft tissues, and radiological features consisting of an exuberant periosteal reaction of the terminal phalanx. The POPP treatment is debated, and side effect risk of therapies may not be offset by their benefits. We report on a successful treatment with carnitine in a 15-year old boy suffering from POPP.
Literature
1.
Fietta P, Manganelli P (2005) Childhood onset of psoriatic onycho-pachydermo-periostitis (POPP). J Eur Acad Dermatol Venereol 19:780–782PubMedCrossRef
2.
Afeltra A, Amoroso A, Sgro P, Gandini L, Lenzi A (2004) Clinical improvement in psoriatic arthritis symptoms during treatment for infertility with carnitine. Clin Exp Rheumatol 22:138PubMed
3.
Fournié B, Viraben R, Durroux R, Lassoued S, Gay R, Fournié A (1989) Psoriatic onycho-pachydermo-periostitis of the big toe. Anatomo-clinical study and physiopathogenic approach apropos of 4 cases. Rev Rhum Mal Osteoartic 56:579–582PubMed
4.
Boisseau-Garsaud AM, Beylot-Barry M, Doutre MS, Beylot C, Baran R (1996) Psoriatic onycho-pachydermo-periostitis. A variant of psoriatic distal interphalangeal arthritis? Arch Dermatol 132:176–180PubMedCrossRef
5.
De Pontville M, Dompmartin A, De Raucourt S, Macro M, Remond B, Leroy D (1993) Psoriatic onycho-pachydermo-periostitis. Ann Dermatol Venereol 120:229–232PubMed
6.
Goupille P, Laulan J, Vedérè V, Kaplan G, Valat JP (1995) Psoriatic onycho-periostitis. Scand J Rheumatol 24:53–54PubMed
7.
Bauza A, Redondo P, Aquerreta D (2000) Psoriatic onycho-pachydermo-periostitis: treatment with methotrexate. Br J Dermatol 143:901–902PubMedCrossRef
8.
Jury CS, Fleming C, Kemmett D (2000) Severe nail dystrophy associated with painful fingertips. Diagnosis: psoriatic onychopachydermoperiostitis (POPP). Arch Dermatol 136:925–930PubMedCrossRef
9.
Dosik JS (2001) Psoriatic onycho-pachydermo-periostitis. Dermatol Online J 7:11PubMed
10.
Kroiss MM, Vogt T, Finkenzeller T, Landthaler M, Stolz W (2002) Psoriatic onycho-pachydermo-periostitis. Z Rheumatol 61:598–600PubMedCrossRef
11.
Anders HJ, Sanden S, Kruger K (2002) Psoriatic onycho-pachydermo-periostitis. Z Rheumatol 61:601–604PubMedCrossRef
12.
Bongartz T, Härle P, Friedrich S, Karrer S, Vogt T, Seitz A et al (2005) Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab. Arthritis Rheum 52:280–282PubMedCrossRef
13.
Kiziltunc A, Cogalgil S, Cerrahoglu L (1998) Carnitine and antioxidant levels in patients with rheumatoid arthritis. Scand J Rheumatol 27:441–445PubMedCrossRef
14.
Azzini M, Girelli D, Olivieri O et al (1995) Fatty acids and anti-oxidant micronutrients in psoriatic arthritis. J Rheumatol 22:103–108PubMed
Metadata
Title
Carnitine: a therapeutic option for childhood psoriatic onycho-pachydermo-periostitis (POPP)
Authors
Pieranna Fietta
Paolo Manganelli
Publication date
01-01-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0322-2

Other articles of this Issue 1/2007

Clinical Rheumatology 1/2007 Go to the issue

Letter to the Editor

Standardization is essential for a more rigorous comparison of rates: comment on the reply by Gilgil, Kacar, and Tuncer

Original Article

The frequency of thyroid antibodies in fibromyalgia patients and their relationship with symptoms

Original Article

The effect of calcitonin on β-endorphin levels in postmenopausal osteoporotic patients with back pain

Brief Report

High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin’s lymphoma

Original Article

Functional disability and health-related quality of life in South Africans with rheumatoid arthritis and systemic lupus erythematosus

Case Report

Delayed diagnosis of systemic lupus erythematosus due to lack of competency skills in musculoskeletal examination
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits